Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fentanyl buccal tablets.

Lynn R Webster1

  • 1Lifetree Clinical Research and Pain Clinic, Salt Lake City, Utah, USA. lynnw@lifetreepain.com

Expert Opinion on Investigational Drugs
|October 17, 2006
PubMed
Summary
This summary is machine-generated.

Fentanyl buccal tablets (FBT) offer effective breakthrough pain relief for chronic pain patients by enhancing fentanyl absorption. While generally well-tolerated, caution is advised for patients with a history of substance abuse due to unknown abuse liability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Purity to Proportionality: Managing Non-Financial Conflicts of Interest in Pain Medicine.

Pain medicine (Malden, Mass.)·2026
Same author

Long-Term Pain Therapy With Opioids.

JAMA·2025
Same author

The impact of medication adherence on health outcomes and cost reduction.

Journal of opioid management·2025
Same author

Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis.

Pain medicine (Malden, Mass.)·2022
Same author

Drug trafficking, good faith, and legal standards to convict: How the United States Supreme Court is about to affect every prescriber in America.

Journal of opioid management·2022
Same author

Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial.

Pain and therapy·2022
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Pain Management
  • Drug Delivery Systems

Background:

  • Chronic pain affects millions, often requiring management of breakthrough pain episodes.
  • Existing opioid analgesics present challenges in absorption and efficacy for rapid pain relief.
  • Fentanyl buccal tablets (FBT) utilize advanced formulation for enhanced transmucosal drug delivery.

Purpose of the Study:

  • To evaluate the safety and tolerability of fentanyl buccal tablets (FBT) in opioid-tolerant patients with chronic pain.
  • To assess the efficacy of FBT in managing breakthrough pain episodes.
  • To explore the potential clinical utility of FBT for anticipated painful events.

Main Methods:

  • Clinical studies involving opioid-tolerant chronic pain patients.

Related Experiment Videos

  • Assessment of safety and tolerability through adverse event monitoring.
  • Evaluation of fentanyl absorption via buccal mucosa, enhanced by an effervescent formulation.

    • Main Results:

    • FBT demonstrated effectiveness and good tolerability in the target patient population.
    • Common adverse events included nausea and somnolence, typically mild to moderate.
    • The formulation's effervescent reaction significantly enhances fentanyl absorption.
    • Low dropout rates suggest acceptable tolerability.

    Conclusions:

    • Fentanyl buccal tablets are a safe and effective option for breakthrough pain in opioid-tolerant patients.
    • The unique effervescent formulation improves fentanyl absorption and efficacy.
    • Potential for use in anticipated painful events exists, but abuse liability requires caution in prescribing.